EVEREST trial
- Conditions
- esophageal squamous cell carcinoma
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 1700
(1) Upper gastrointestinal endoscopy for surveillance after endoscopic resection of histopathologically diagnosed primary esophageal squamous cell carcinoma (ESCC) is planned. (2) Histopathology of all endoscopic resections was pT1a, negative for lymphovascular invasion, and negative for vertical margin. (3) The previous upper gastrointestinal endoscopy with iodine staining of the entire esophagus was performed within 6 months, and all histopathologically diagnosed ESCCs were endoscopically resected. (4) Additional treatment is not planned after endoscopic resection of ESCC. (5) No previous treatment for ESCC other than endoscopic resection. (6) No previous radiation therapy for the chest, lung field, or mediastinum for any cancer types. (7) No previous surgery for the esophagus or mediastinum including for benign tumors. (8) No pharyngeal or esophageal stricture where the standard endoscope cannot pass. (9) Age between 18 and 80 years. (10) An Eastern Cooperative Oncology Group Performance Status of 0 or 1. (11) Endoscopic surveillance for 3 years after registration is considered feasible. (12) Provision of written informed consent for participation in the trial.
(1) Other primary cancers within the previous 5 years except intramucosal tumors cured with local therapy. (2) A history of iodine allergy. (3) Severe mental disease. (4) The investigator considered ineligible as subjects.
Study & Design
- Study Type
- Interventional
- Study Design
- parallel assignment
- Primary Outcome Measures
Name Time Method - Targeted ESCC-free survival
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.